<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101235741</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32200</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Med Genet A</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Med. Genet. A</journal-id>
<journal-title-group>
<journal-title>American journal of medical genetics. Part A</journal-title>
</journal-title-group>
<issn pub-type="ppub">1552-4825</issn>
<issn pub-type="epub">1552-4833</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31654560</article-id>
<article-id pub-id-type="pmc">7334030</article-id>
<article-id pub-id-type="doi">10.1002/ajmg.a.61385</article-id>
<article-id pub-id-type="manuscript">NIHMS1598951</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Behavioral characterization of dup15q syndrome: Toward meaningful endpoints for clinical trials</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>DiStefano</surname>
<given-names>Charlotte</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1927-8590</contrib-id>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilson</surname>
<given-names>Rujuta B.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hyde</surname>
<given-names>Carly</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cook</surname>
<given-names>Edwin H.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thibert</surname>
<given-names>Ronald L.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Reiter</surname>
<given-names>Lawrence T.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vogel-Farley</surname>
<given-names>Vanessa</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hipp</surname>
<given-names>Joerg</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jeste</surname>
<given-names>Shafali</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, California</aff>
<aff id="A2"><label>2</label>Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois</aff>
<aff id="A3"><label>3</label>Department of Neurology, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts</aff>
<aff id="A4"><label>4</label>Department of Neurology, Pediatrics, Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, Tennessee</aff>
<aff id="A5"><label>5</label>Dup15q Alliance, Highland Park, Illinois</aff>
<aff id="A6"><label>6</label>Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center, Basel, Switzerland</aff>
<author-notes>
<corresp id="CR1"><bold>Correspondence:</bold> Charlotte DiStefano, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA. <email>cdistefano@mednet.ucla.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P52">CONFLICT OF INTEREST</p>
<p id="P53">Vanessa Vogel-Farley is an employee of the Dupl5q Alliance. Joerg F. Hipp is an employee of F. Hoffmann-La Roche Ltd. Shafali Jeste serves as a consultant for and has received funding from F. Hoffmann-La Roche Ltd. and Yamo Pharmaceuticals. C. DiStefano, R. Wilson, C. Hyde, E. H. Cook, R. L. Thibert, and L. T. Reiter have no conflicts of interest to declare.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>4</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>03</day>
<month>7</month>
<year>2020</year>
</pub-date>
<volume>182</volume>
<issue>1</issue>
<fpage>71</fpage>
<lpage>84</lpage>
<!--elocation-id from pubmed: 10.1002/ajmg.a.61385-->
<abstract id="ABS1">
<p id="P1">Duplication of 15qll.2-ql3.1 (dupl5q syndrome) is one of the most common copy number variations associated with autism spectrum disorders (ASD) and intellectual disability (ID). As with many neurogenetic conditions, accurate behavioral assessment is challenging due to the level of impairment and heterogeneity across individuals. Largescale phenotyping studies are necessary to inform future clinical trials in this and similar ID syndromes. This study assessed developmental and behavioral characteristics in a large cohort of children with dupl5q syndrome, and examined differences based on genetic subtype and epilepsy status. Participants included 62 children (2.5â€“18 years). Across individuals, there was a wide range of abilities. Although adaptive behavior was strongly associated with cognitive ability, adaptive abilities were higher than cognitive scores. Measures of ASD symptoms were associated with cognitive ability, while parent report of challenging behavior was not. Both genetic subtype and epilepsy were related to degree of impairment across cognitive, language, motor, and adaptive domains. Children with isodicentric duplications and epilepsy showed the greatest impairment, while children with interstitial duplications showed the least. On average, participants with epilepsy experienced seizures over 53% of their lives, and half of children with epilepsy had infantile spasms. Parents of children with isodicentric duplications reported more concerns regarding challenging behaviors. Future trials in ID syndromes should employ a flexible set of assessments, allowing each participant to receive assessments that capture their skills. Multiple sources of information should be considered, and the impact of language and cognitive ability should be taken into consideration when interpreting results.</p>
</abstract>
<kwd-group>
<kwd>behavioral assessment</kwd>
<kwd>dupl5q syndrome</kwd>
<kwd>epilepsy</kwd>
<kwd>intellectual disability</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>